Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, Prospective Study of the Safety of GSK Biologicals' Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO).

Trial Profile

Open, Prospective Study of the Safety of GSK Biologicals' Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO).

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Aug 2012 Actual patient number changed from 25936 to 10000 as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Results published in The Pediatric Infectious Disease Journal.
    • 10 Sep 2008 Actual patient number (25936) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top